Bradykinin Protects Against Oxidative Stress–Induced Endothelial Cell Senescence

Premature aging (senescence) of endothelial cells might play an important role in the development and progression of hypertension and atherosclerosis. We hypothesized that bradykinin, a hormone that mediates vasoprotective effects of angiotensin-converting enzyme inhibitors, protects endothelial cells from oxidative stress–induced senescence. Bradykinin treatment (0.001 to 1 nmol/L) dose-dependently decreased senescence induced by 25 &mgr;mol/L of H2O2 in cultured bovine aortic endothelial cells, as witnessed by a complete inhibition of increased senescent cell numbers and a 34% reduction of the levels of the senescence-associated cell cycle protein p21. Because H2O2 induces senescence through superoxide-induced DNA damage, single-cell DNA damage was measured by comet assay. Bradykinin reduced DNA damage to control levels. The protective effect of bradykinin also resulted in a significant increase in the migration of H2O2-treated bovine aorta endothelial cells in an in vitro endothelial injury model, or “scratch” assay. The protective effect of bradykinin was abolished by the bradykinin B2 receptor antagonist HOE-140 and the NO production inhibitor N&ohgr;-methyl-l-arginine acetate salt. Therefore, we conclude that bradykinin protects endothelial cells from superoxide-induced senescence through bradykinin B2 receptor– and NO-mediated inhibition of DNA damage.

[1]  P. Harst,et al.  Bradykinin protects against endothelial cell senescence , 2008 .

[2]  T. Littlewood,et al.  Statins Use a Novel Nijmegen Breakage Syndrome-1–Dependent Pathway to Accelerate DNA Repair in Vascular Smooth Muscle Cells , 2008, Circulation research.

[3]  N. Samani,et al.  Biological ageing and cardiovascular disease , 2008, Heart.

[4]  B. Williams,et al.  Angiotensin II–Mediated Oxidative DNA Damage Accelerates Cellular Senescence in Cultured Human Vascular Smooth Muscle Cells via Telomere-Dependent and Independent Pathways , 2008, Circulation research.

[5]  M. Quintero,et al.  Evidence against the involvement of nitric oxide in the modulation of telomerase activity or replicative capacity of human endothelial cells , 2007, Experimental Gerontology.

[6]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[7]  I. Komuro,et al.  Vascular Cell Senescence: Contribution to Atherosclerosis , 2007, Circulation research.

[8]  L. Ignarro,et al.  Endothelial cellular senescence is inhibited by nitric oxide: Implications in atherosclerosis associated with menopause and diabetes , 2006, Proceedings of the National Academy of Sciences.

[9]  C. R. Bagnell,et al.  Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. , 2006, The Journal of clinical investigation.

[10]  J. Pesquero,et al.  Genetically altered animal models in the kallikrein-kinin system , 2006, Biological chemistry.

[11]  L. Truong,et al.  Loss of nitric oxide and endothelial-derived hyperpolarizing factor-mediated responses in aging. , 2005, Kidney international.

[12]  Christian R Gomez,et al.  Increased kinin levels and decreased responsiveness to kinins during aging. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  J. Folkman,et al.  CDK2 translational down-regulation during endothelial senescence. , 2005, Experimental cell research.

[14]  R. Weinberg,et al.  The signals and pathways activating cellular senescence. , 2005, The international journal of biochemistry & cell biology.

[15]  H. Gavras,et al.  Age-related changes of bradykinin B1 and B2 receptors in rat heart. , 2005, American journal of physiology. Heart and circulatory physiology.

[16]  T. Imanishi,et al.  Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress , 2005, Journal of hypertension.

[17]  L. M. Leeb-Lundberg.  Bradykinin specificity and signaling at GPR100 and B2 kinin receptors. , 2004, British journal of pharmacology.

[18]  P. van der Harst,et al.  Vascular Response to Angiotensin II Predicts Long-Term Prognosis in Patients Undergoing Coronary Artery Bypass Grafting , 2004, Hypertension.

[19]  P. Corvol,et al.  Effect of Reduced Angiotensin-Converting Enzyme Gene Expression and Angiotensin-Converting Enzyme Inhibition on Angiotensin and Bradykinin Peptide Levels in Mice , 2004, Hypertension.

[20]  W. Zwerschke,et al.  Senescence-associated cell death of human endothelial cells: the role of oxidative stress , 2003, Experimental Gerontology.

[21]  Tomasz Kuszewski,et al.  A cross-platform public domain PC image-analysis program for the comet assay. , 2003, Mutation research.

[22]  Daniel Levy,et al.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. , 2003, Circulation.

[23]  I. Komuro,et al.  [Endothelial cell senescence in human atherosclerosis: role of telomeres in endothelial dysfunction]. , 2003, Journal of cardiology.

[24]  I. Komuro,et al.  Endothelial Cell Senescence in Human Atherosclerosis: Role of Telomere in Endothelial Dysfunction , 2002, Circulation.

[25]  A. Danser,et al.  Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade , 2001, Hypertension.

[26]  M. Fujishima,et al.  Renin-Angiotensin System Blockade Improves Endothelial Dysfunction in Hypertension , 2000, Hypertension.

[27]  A. Zeiher,et al.  Nitric Oxide Activates Telomerase and Delays Endothelial Cell Senescence , 2000, Circulation research.

[28]  Z. Saifudeen,et al.  The Bradykinin Type 2 Receptor Is a Target for p53-mediated Transcriptional Activation* , 2000, The Journal of Biological Chemistry.

[29]  R. Minshall,et al.  Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells. , 1997, Circulation research.

[30]  K. Yamanouchi,et al.  Aging decreases the production of PGI2 in rat aortic endothelial cells , 1997, Experimental Gerontology.

[31]  D. Campbell,et al.  Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. , 1996, Journal of cardiovascular pharmacology.

[32]  G. B. John Mancini,et al.  Angiotensin Converting Enzyme Inhibition, with Quinapril, Improves Endothelial Vasomotor Dysfunction in Patients with Coronary Artery Disease: the TREND Study (Trial on REversing ENdothelial Dysfunction) , 1996 .

[33]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Ghiadoni,et al.  Aging and endothelial function in normotensive subjects and patients with essential hypertension. , 1995, Circulation.

[35]  I. Morita,et al.  Augmentation of endothelin-1, prostacyclin and thromboxane A2 secretion associated with in vitro ageing in cultured human umbilical vein endothelial cells , 1993, Mechanisms of Ageing and Development.

[36]  Y. Christen,et al.  Determinants of angiotensin II generation during converting enzyme inhibition. , 1990, Hypertension.

[37]  J. Biollaz,et al.  Antihypertensive Therapy with MK 4211: Angiotensin II‐Renin Relationships to Evaluate Efficacy of Converting Enzyme Blockade , 1982, Journal of cardiovascular pharmacology.